{
    "title": "103_hr1926",
    "content": "The Act titled \"National Narcotics Leadership Act Amendments of 1993\" implements the National Drug Control Strategy. The National Narcotics Leadership Act of 1988 is amended to allow the Director to require funding requests for specific initiatives in the budget submission to the Office of Management and Budget by National Drug Control Program agencies. SEC. 3. REPORT ON REPROGRAMMING; OFFICE PERSONNEL RESTRICTION. The Director must report quarterly to Congress on the need for reprogramming funds over $5,000,000 for National Drug Control Program activities. Additionally, a prohibition on political campaigning is imposed on Federal officers in the Office of National Drug Control Policy. The Director of the Office of National Drug Control Policy, appointed by the President with Senate approval, is restricted from participating in Federal election campaign activities, but can still make contributions to individual candidates. The National Drug Control Strategy Outcome Measures are outlined in Section 4. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy. This evaluation will assess the reduction of drug use and the consequences of drug abuse. The evaluation of drug control effectiveness in the National Drug Control Strategy includes estimates of drug prevalence and frequency of use, measured by national, State, and local surveys, special studies on high-risk populations, and drug availability reduction assessment. The evaluation of drug control effectiveness in the National Drug Control Strategy includes measuring availability through quantities of cocaine, heroin, and marijuana, amounts entering the US, hectares of poppy and coca cultivated, metric tons of heroin and cocaine seized, and cocaine processing labs destroyed. The evaluation of drug control effectiveness in the National Drug Control Strategy includes measuring changes in the price and purity of heroin and cocaine, controlled substances diverted from legitimate sources, and the effectiveness of Federal technology programs at improving drug detection capabilities at US ports of entry. The curr_chunk focuses on estimating the burdens drug users place on hospital emergency rooms in the United States, including drug-related services provided, national healthcare costs of drug use, costs associated with HIV and other diseases from drug use, and the extent of drug-related crime and criminal activity. The curr_chunk assesses drug treatment capacity in the United States, including public and private treatment availability, number of treatment slots, and data on intravenous drug users and pregnant women. The curr_chunk evaluates the availability of treatment for intravenous drug users and pregnant women, the estimated number of drug users who could benefit from treatment, and the success of drug treatment programs at federal and state levels. The Director will assess substance abuse treatment programs federally and within each State to determine quality, personnel qualifications, and patient admission mechanisms. This assessment will be included in the National Drug Control Strategy submitted every second year. The Director will assess drug use measurement instruments and techniques, coverage of national drug use measurement instruments, and actions to correct deficiencies identified. The Director will assess drug use measurement instruments, coverage, and corrective actions. Federal agencies must cooperate to provide drug-related information for the Director to meet requirements. The Director is required to report on drug use and availability in the US, including the effectiveness of various programs under the National Drug Control Strategy. SEC. 5 amends title 50, United States Code, to include the Director of the Office of National Drug Control Policy as a member of the National Security Council. SEC. 6 establishes the Counter-Drug Technology Assessment Center. The National Narcotics Leadership Act of 1988 is amended to identify and support the application of technology for drug treatment effectiveness. The National Narcotics Leadership Act of 1988 is amended to provide assistance and support from the Advanced Research Project Agency to the Office of National Drug Control Policy. Section 1008 is repealed and redesignated. The National Narcotics Leadership Act of 1988 is amended to provide support from the Advanced Research Project Agency to the Office of National Drug Control Policy by repealing and redesignating section 1008. This involves moving the section to follow section 1007. SEC. 7. The Director can pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8. Authorization of appropriations for fiscal year 1994. SEC. 9 of the National Narcotics Leadership Act of 1988 is amended to terminate the Office of National Drug Control Policy on September 30, 1994."
}